153 related articles for article (PubMed ID: 20833478)
41. Applications and challenges in therapeutic drug monitoring of cancer treatment: A review.
Salman B; Al-Khabori M
J Oncol Pharm Pract; 2021 Apr; 27(3):693-701. PubMed ID: 33302823
[TBL] [Abstract][Full Text] [Related]
42. Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure.
Rowland A; van Dyk M; Mangoni AA; Miners JO; McKinnon RA; Wiese MD; Rowland A; Kichenadasse G; Gurney H; Sorich MJ
Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):31-49. PubMed ID: 27561659
[TBL] [Abstract][Full Text] [Related]
43. Molecular Targets in Advanced Therapeutics of Cancers: The Role of Pharmacogenetics.
Abubakar MB; Gan SH
Oncology; 2016; 91(1):3-12. PubMed ID: 27233906
[TBL] [Abstract][Full Text] [Related]
44. Blood retinal barrier and ocular pharmacokinetics: Considerations for the development of oncology drugs.
Williamson B; Pilla Reddy V
Biopharm Drug Dispos; 2021 Apr; 42(4):128-136. PubMed ID: 33759216
[TBL] [Abstract][Full Text] [Related]
45. Model-Based Biomarker Selection for Dose Individualization of Tyrosine-Kinase Inhibitors.
Centanni M; Friberg LE
Front Pharmacol; 2020; 11():316. PubMed ID: 32226388
[TBL] [Abstract][Full Text] [Related]
46. [Issues of oral targeted therapies in daily clinical practice: 5th edition of the congress of pharmacology of anticancer drugs].
Zaibet S; Vauchier C; Khoudour N; Roulleaux Dugage M; Korb-Savoldelli V; Alexandre J; Blanchet B; Goldwasser F; Thomas-Schoemann A; Bellesoeur A
Bull Cancer; 2018 Nov; 105(11):1102-1109. PubMed ID: 30309623
[TBL] [Abstract][Full Text] [Related]
47. Hematologic toxicities of small molecule tyrosine kinase inhibitors.
Barber NA; Afzal W; Akhtari M
Target Oncol; 2011 Dec; 6(4):203-15. PubMed ID: 22127751
[TBL] [Abstract][Full Text] [Related]
48. [Targeted therapeutics and their role in the treatment of internal diseases].
Klener P
Vnitr Lek; 2013 Jan; 59(1):5-12. PubMed ID: 23427997
[TBL] [Abstract][Full Text] [Related]
49. Nuances to precision dosing strategies of targeted cancer medicines.
Hopkins AM; Menz BD; Wiese MD; Kichenadasse G; Gurney H; McKinnon RA; Rowland A; Sorich MJ
Pharmacol Res Perspect; 2020 Aug; 8(4):e00625. PubMed ID: 32662214
[TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetic considerations for new targeted therapies.
Baker SD; Hu S
Clin Pharmacol Ther; 2009 Feb; 85(2):208-11. PubMed ID: 19092780
[TBL] [Abstract][Full Text] [Related]
51. Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer.
Puisset F; Mseddi M; Mourey L; Pouessel D; Blanchet B; Chatelut E; Chevreau C
Cancers (Basel); 2023 Jan; 15(1):. PubMed ID: 36612311
[TBL] [Abstract][Full Text] [Related]
52. Changing pathology with changing drugs.
Borisch B; Hoessli D
Pathobiology; 2011; 78(2):59-60. PubMed ID: 21677469
[No Abstract] [Full Text] [Related]
53. [Future direction of medical oncology in Japan].
Nakagawa K
Nihon Rinsho; 2012 Nov; 70 Suppl 8():1-4. PubMed ID: 23513802
[No Abstract] [Full Text] [Related]
54. [Progress of molecular targeted therapies].
Hayashi H; Nishio K
Nihon Rinsho; 2012 Nov; 70 Suppl 8():7-11. PubMed ID: 23513803
[No Abstract] [Full Text] [Related]
55. Drug-target interactions: Stay tuned.
Copeland RA
Nat Chem Biol; 2015 Jul; 11(7):451-2. PubMed ID: 26006012
[No Abstract] [Full Text] [Related]
56. Inhibitors of mTOR pathway for cancer therapy, moving on from rapalogs to TORKinibs.
Owonikoko TK
Cancer; 2015 Oct; 121(19):3390-2. PubMed ID: 26177743
[No Abstract] [Full Text] [Related]
57. Individualization.
Homoeopath Physician; 1894 May; 14(5):129-130. PubMed ID: 37136847
[No Abstract] [Full Text] [Related]
58. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.
Yu H; Steeghs N; Nijenhuis CM; Schellens JH; Beijnen JH; Huitema AD
Clin Pharmacokinet; 2014 Apr; 53(4):305-25. PubMed ID: 24566736
[TBL] [Abstract][Full Text] [Related]
59. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors.
Terada T; Noda S; Inui K
Pharmacol Ther; 2015 Aug; 152():125-34. PubMed ID: 25976912
[TBL] [Abstract][Full Text] [Related]
60. Therapeutic drug monitoring to personalize dosing of imatinib, sunitinib, and pazopanib: A mixed methods study on barriers and facilitators.
Westerdijk K; Steeghs N; Tacke CSJ; van der Graaf WTA; van Erp NP; van Oortmerssen G; Hermens RPMG; Desar IME;
Cancer Med; 2023 Nov; 12(22):21041-21056. PubMed ID: 37902257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
